LHSC: Victoria Hospital

London, Ontario ON N6A 5W9

3 studies enrolling now · 27 studies all time

What they study most

Allogeneic Hematopoietic Stem Cell Transplantation, Alpha1-antitrypsin Deficiency, Antibiotic-associated Diarrhea, Blood Cancer, C-Difficile, Cardiovascular Diseases, Chronic Graft-versus-Host-Disease, Chronic Obstructive Pulmonary Disease, Colitis, Ulcerative, Connective Tissue Diseases, Crohn Disease, Crohn's Disease

Studies at this site

• A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease — Recruiting now
• VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease — Recruiting now
• Research Study Investigating How Well NDec Works in People With Sickle Cell Disease — Completed
• A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients — Completed
• A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension — Enrolling by invitation
• Determination of the Optimal Treatment Target in Ulcerative Colitis — Running, not enrolling
• A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) — Completed
• Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) — Running, not enrolling
• A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma — Completed
• A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease — Completed
• Polyomic Biomarker Verification in Adult Chronic Graft-Versus-Host Disease (ABLE3.0/CTTC2201) — Status unconfirmed
• Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis — Completed
• Triple Combination Therapy in High Risk Crohn's Disease (CD) — Completed
• Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis — Completed
• Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD) — Completed
• A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's Disease — Completed
• A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer — Completed
• GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study — Completed
• Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis — Completed
• Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease — Stopped early
• Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency — Stopped early
• Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease — Completed
• Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial — Completed
• An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis — Completed
• Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease — Stopped early
• A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease — Stopped early
• A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease — Withdrawn before enrolling